Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

4.250 -22.230 (-83.95%)
Streaming Delayed Price Updated: 9:54 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Cassava Sciences Names Rick Barry as Chief Executive Officer
Claude Nicaise, M.D. appointed Chairman of the Board 
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance. 
Via MarketBeat
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Market Whales and Their Recent Bets on SAVA Options
Via Benzinga
What's Going On With Cassava Sciences Today?
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday. Here's what you need to know. 
Via Benzinga
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences News: Why Is SAVA Stock Trending Today?
Cassava Sciences stock is down on Tuesday even as investors take note of SAVA shares alongside a couple of pieces of news. 
Via InvestorPlace
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
From Cassava Sciences, Inc.
Via GlobeNewswire
(SAVA) - Analyzing Cassava Sciences's Short Interest
Via Benzinga
What's Going On With Cassava Sciences Shares Today?
Cassava Sciences is set to report its second-quarter earnings on Aug. 13, with an anticipated loss of 40 cents per share, according to Benzinga Pro. 
Via Benzinga
Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Cassava Sciences Shares Are Trading Higher Today: What You Need To Know
Cassava Sciences, Inc. (NASDAQ: SAVA) saw its stock price soar by 15.5% to $27.13, an increase of $3.64, amid rising short interest and an anticipated conference call to discuss recent developments. 
Via Benzinga
Get Your Money Out of These 3 Healthcare Stocks ASAP
Many companies in the healthcare sector have great outlooks but these healthcare stocks to sell are facing very tough challenges 
Via InvestorPlace
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
From Cassava Sciences, Inc.
Via GlobeNewswire
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
SmartRent (SMRT) Stock Plunges 21% as CEO Steps Down
SmartRent stock is falling on Tuesday as SMRT investors react to the resignation of the company's CEO and suspension of its 2024 outlook. 
Via InvestorPlace
Microsoft Office Outage: Microsoft Investigates Applications, Services Issue
A Microsoft Office outage has workers annoyed as its causing problems with them being able to use the company's services. 
Via InvestorPlace
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
Cassava Sciences has announced plans to extend trials for its Alzheimer’s treatment drug. This news isn't helping SAVA stock. 
Via InvestorPlace
Cassava Sciences Announces Expansion of Open-Label Extension Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Get Your Money Out of These 3 Biotech Stocks Before the End of July
These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies. 
Via InvestorPlace
Nasdaq Up Triple Digits Amid Tech Resurgence
The Nasdaq Composite Index is up 190 points as Big Tech stages a comeback following last week's selloff. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials
Cassava Sciences' Phase 3 trials for Alzheimer's drug simufilam could change treatment standards. With trials costing millions, success could revolutionize care for millions. CEO emphasizes... 
Via Benzinga
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?
MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog. 
Via InvestorPlace
RDDT Stock Alert: Reddit Nabs New Deals with NFL, NBA
Reddit stock is up on Monday after investors in RDDT learned of the company signing new deals with sports leagues for content. 
Via InvestorPlace
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
Cassava Sciences stock is up on Monday after the company provided SAVA investors with an update on its upcoming clinical trial data. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.